Sign In
Buy ABBV
$224.93
+7.86 (+3.62%)
At Close: Jun 04, 2026
What Is the Intent Behind AbbVie's Recent Acquisition Spree?
12:20pm, Wednesday, 27'th Aug 2025
ABBV's $1.2B neuroscience deal and 30+ acquisitions highlight its push to expand beyond immunology into obesity, oncology and brain health.
AbbVie: Plenty Of Positives
01:24pm, Tuesday, 26'th Aug 2025
AbbVie has had a good August, with double digit MoM gains after seeing weakness for six months. Factors like an EU-US deal on pharmaceuticals, recent results, improved guidance, positive outcomes in
ABBV Buys Rights to Bretisilocin, a Novel Psychedelic for Depression
09:10am, Tuesday, 26'th Aug 2025
AbbVie ABBV has announced a deal with private neuroscience biotech, Gilgamesh Pharmaceuticals, to acquire the latter's lead pipeline candidate, bretisilocin (GM-2505), a novel therapy being developed
AbbVie Is A Top Biotech Pick
09:18am, Monday, 25'th Aug 2025
Q2 earnings results were strong for AbbVie as top line growth is at a historically high level and operating margin expanded due to SG&A efficiencies. The company's Rinvoq drug has new market potential
AbbVie to buy Gilgamesh Pharma's depression drug for up to $1.2 billion
09:09am, Monday, 25'th Aug 2025
AbbVie said on Monday it would buy privately held Gilgamesh Pharmaceuticals' treatment for major depressive disorder in a deal worth up to $1.2 billion.
Gilgamesh's lead asset, bretisilocin (GM-2505), is a potential best-in-class psychedelic compound currently in Phase 2 development for the treatment of major depressive disorder (MDD). Bretisilocin is
Best Dividend Kings: August 2025
10:13pm, Sunday, 24'th Aug 2025
Dividend Kings underperformed SPY year-to-date but are showing stronger gains in August, with several stocks achieving double-digit returns in 2025. Fifteen Dividend Kings currently appear undervalued
3 Top Stocks to Build Your Portfolio Around
09:15am, Sunday, 24'th Aug 2025
Building a portfolio capable of earning strong returns over long periods is not easy, but there are some basic principles we can try to follow to simplify the task. One is to start with companies that
AbbVie Investors Beware: Strong Growth Potential, Rising Risks
10:31am, Saturday, 23'rd Aug 2025
AbbVie has delivered strong total returns and dividend growth over time. Additionally, it enjoys strong growth prospects. However, it also faces significant uncertainty and risks.
3 Unstoppable Dividend Stocks to Buy Right Now
06:45am, Saturday, 23'rd Aug 2025
How does getting paid to own a stock sound to you? That's exactly what dividends do.
AbbVie Pins Hopes on Rinvoq to Drive Next Phase of Growth
10:41am, Friday, 22'nd Aug 2025
ABBV posts strong phase III alopecia areata data from the second study on Rinvoq. The drug hit $3.7B in H1 sales and is expected to further drive growth in H2.
ABBV's Improving Oncology Sales Poise It Well for Long-Term Growth
09:46am, Friday, 22'nd Aug 2025
AbbVie's oncology sales climbed 4.2% in H1 2025 as new drugs offset Imbruvica declines, strengthening its long-term growth outlook.
AbbVie Announces Positive Topline Results from Second Phase 3 UP-AA Trial Evaluating Upadacitinib (RINVOQ®) for Alopecia Areata
08:30am, Thursday, 21'st Aug 2025
In the second replicate study (Study 1) of the pivotal Phase 3 UP-AA clinical program, upadacitinib (RINVOQ®) achieved the primary endpoint, demonstrating that 45.2% and 55.0% of patients with severe
2 High-Yield Dividend Stocks to Buy in August and Hold for a Decade or Longer
07:44am, Thursday, 21'st Aug 2025
High yield can sometimes lead to high turnover. Income investors may need to be prepared to sell high-yield dividend stocks quickly if their dividends appear to be at risk.
AbbVie Rises 11.5% in a Month: Buy, Hold or Sell the Stock?
10:42am, Wednesday, 20'th Aug 2025
AbbVie jumps 11.5% in a month on strong Q2 results, raised guidance and momentum from Skyrizi, Rinvoq and neuroscience growth.
